ARTICLE | Clinical News
TNKase tenecteplase: Marketed in U.S.; under review in Europe
August 27, 2001 7:00 AM UTC
Patients given TNKase plus Clexane had an event rate of 13.75% compared to 17.04% for TNKase and UFH (p=0.0081). The TNKase plus UFH and ReoPro group had an event rate of 14.24%, which was lower than ...